Board of
Directors
Directors
Martin Babler
Fred Dotzler
David Henkel-Wallace
Robert L. Roe, M.D
Jane E. Shaw, PhD
Jim Woody M.D, PhD
Phil Young
Fred earned an MBA from the University of Chicago, a Master’s equivalent in Economics from the University of Louvain, Belgium and a BS in Engineering from Iowa State University, where he received a Professional Achievement Citation in Engineering in 2000. He is a member of the Advisory Board of the Journal of Private Equity.
Mr. Henkel-Wallace was a co-founder of The Little Garden, one of the first commercial ISPs, now part of NTT. He also co-founded Cygnus Solutions, the first of the Open Source Software companies and the company that developed the business model and viability of the sector, subsequently merged into Red Hat. He was also a founder of Zembu Labs, a developer of distributed database technology. Previously, Mr. Henkel-Wallace was a researcher at Xerox PARC, MIT’s Artificial Intelligence Laboratory, and the Microelectronics and Computer Consortium. Mr. Henkel-Wallace has worked with major venture capital firms including August Capital, Greylock, Hummer Winblad and Oak Hill Venture Partners.
Mr. Henkel-Wallace founded Talima in early 2004 and served as the Company’s first CEO until December 2007. He continues to sit on the Board of Talima. Mr. Henkel-Wallace is a graduate of the Massachusetts Institute of Technology.
Prior to Centocor, Jim served as Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. In that role, he was responsible for a wide range of medical research and development activities ranging from transplantation research to infectious diseases. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War, and was awarded the US Navy Legion of Merit for his service.
Jim holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. Jim has authored or co-authored over 140 publications.
"Ultimately companies are run by the CEO and management team. Good board members know that the CEO, and only the CEO, makes both the final decisions and manages the execution. But good CEOs will solicit substantive input from their board, and benefit from the dialectic resulting from the meaningful debate of issues at the board level. I really enjoy the process when it's useful."
Phil has finely honed his sense for effective contribution to the companies he advises:
"Sometimes it's best to run alongside the CEO, other times it's best to coach from the sidelines."
Execution is management's responsibility, but board members can be useful sounding boards. "Increasingly, business models are less straightforward. It's helpful to draw out the board's expertise and experience from seeing recurring patterns across industries and over time."
Prior to joining USVP in 1990, Phil spent four years with Concord Partners, Dillon Read's venture capital operation in Palo Alto. With a specialty in the medical device industry, Phil has watched the evolution of new methodologies, such as the emergence of minimally-invasive treatments, into increasingly diverse and pervasive applications.
"In this industry, you need to look at the clinician's perspectives on the market opportunity as well as the investment and technology sides," notes Phil. "Minimally-invasive procedures are still in their infancy."
Phil's investment interests aren't confined to medical devices and biotechnology, however. Recently he's been active in online advertising, a more than $10 billion industry growing at nearly 30 percent a year.
"A critical need in online advertising is helping companies find scalable business models that work," notes Phil.
Like other USVP partners, Phil arrived with extensive operating experience. He was President and CEO of Oximetrix, a manufacturer of critical care instruments and disposables, where he spent eight years growing the privately held venture-backed company from $1 million in revenues to nearly $50 million. Prior to Oximetrix, Phil spent six years at New Court Securities in venture capital and corporate finance, two years as a management consultant with McKinsey & Co., and six years on Admiral Rickover's project management staff at the Atomic Energy Commission.
He has represented USVP on the boards of Aerogen, CardioThoracic Systems, CardioVascular Imaging Systems, CoCensys, Compugen, FemRx, Penederm, 3Dfx Interactive, Vical and Xoma—all of which became public companies, and on the boards of RelayHealth and St. Francis Medical Technologies which were acquired. Currently he sits on the boards of Zoran, a public company, and privately held Aptus Endosystems, Bayhill Therapeutics, Claria, Dotomi, Synarc, Talima Therapeutics, and Timi3 Systems. He also serves on the Board of Trustees of Cornell University and as Chairman of the Board of eCornell, the university's online distance learning subsidiary.
Phil earned a B.M.E. from Cornell University with High Distinction, an M.S. in Engineering Physics from George Washington University, and an M.B.A. with High Distinction from Harvard, where he was a Baker Scholar.
Phil enjoys photography, cooking and spending time with his wife in the South of France. He has two daughters and three grandchildren.
Fred Dotzler
David Henkel-Wallace
Robert L. Roe, M.D
Jane E. Shaw, PhD
Jim Woody M.D, PhD
Phil Young
Martin Babler
Mr. Babler is President and Chief Executive Officer of Talima Therapeutics, Inc, a position he has held since December of 2007. From 1998 to 2006 he worked at Genentech where he served as Vice President of Immunology Sales and Marketing, Senior Director of Commercial Development and Director of Cardiovascular Marketing. Prior to joining Genentech, Mr. Babler held various roles of increasing responsibility in sales, sales management, marketing and business development with Eli Lilly and Company. Mr. Babler is a faculty member of the BioExec Institute, a BioPharma Executive Education series at the Haas School of Business and he is a director of Infinity Pharmaceuticals. Mr. Babler holds a degree in Pharmacy from the ETH in Zurich, Switzerland and has attended the Executive Development Program at Kellogg Graduate School of Management.
Fred Dotzler
Mr. Dotzler is a partner and co-founder of De Novo ventures since 2000. Prior to De Novo, he was a Managing General Partner of Medicus Venture Partners (“Medicus”), which he founded in 1989. His tenure at Medicus was preceded by 5 years with Crosspoint Venture Partners as General partner investing in life sciences companies. Prior to joining Crosspoint, Mr. Dotzler served in executive positions in finance, marketing, sales, manufacturing and business development for companies selling pharmaceuticals (Searle), medical instruments (Merrimack), biotechnology research tools (Millipore), and computers (IBM). Mr. Dotzler is also a board member of Astute Medical, Bayhill Therapeutics, HemaQuest and SenoRx (NASDAQ: SENO), and he represented De Novo on investments in Favrille, Microvention, Oncomed and Renovis.
Fred earned an MBA from the University of Chicago, a Master’s equivalent in Economics from the University of Louvain, Belgium and a BS in Engineering from Iowa State University, where he received a Professional Achievement Citation in Engineering in 2000. He is a member of the Advisory Board of the Journal of Private Equity.
David Henkel-Wallace
Mr. Henkel-Wallace is a pioneering entrepreneur with extensive experience in developing new business areas and a track record of selling successful, profitable businesses.
Mr. Henkel-Wallace was a co-founder of The Little Garden, one of the first commercial ISPs, now part of NTT. He also co-founded Cygnus Solutions, the first of the Open Source Software companies and the company that developed the business model and viability of the sector, subsequently merged into Red Hat. He was also a founder of Zembu Labs, a developer of distributed database technology. Previously, Mr. Henkel-Wallace was a researcher at Xerox PARC, MIT’s Artificial Intelligence Laboratory, and the Microelectronics and Computer Consortium. Mr. Henkel-Wallace has worked with major venture capital firms including August Capital, Greylock, Hummer Winblad and Oak Hill Venture Partners.
Mr. Henkel-Wallace founded Talima in early 2004 and served as the Company’s first CEO until December 2007. He continues to sit on the Board of Talima. Mr. Henkel-Wallace is a graduate of the Massachusetts Institute of Technology.
Robert L. Roe, M.D.
Dr. Roe joined Corcept as President in October 2001. Dr. Roe has spent more than 30 years in the pharmaceutical and biotechnology industries. From 1999 to 2001, he served as President and Chief Executive Officer of Allergenics, Inc. From 1996 to 1999, Dr. Roe was Executive Vice President, Chief Operating Officer and a director of Cytel Corporation. From 1995 to 1996, he was Executive Vice President, Chief Operating Officer and a director of Chugai Biopharmaceuticals, Inc. From 1992 to 1995, Dr. Roe served as President of the Development Research Division and Senior Vice President of Syntex Corporation. Dr. Roe received his A.B. from Stanford University and his M.D. from the University of California, San Francisco.
Jane E. Shaw, PhD
Dr. Shaw served as Chief Executive Officer of Aerogen Inc., a specialty pharmaceutical company from 1998 to June 30, 2005. Dr. Shaw founded Stable Network, a biopharmaceutical consulting firm, in 1995 and worked as a Consultant in the biopharmaceutical industry since that time. Dr. Shaw held various scientific and management positions with ALZA Corporation, a pharmaceutical company from 1970 to 1994, and served as its President and Chief Operating Officer from 1987 to 1994. She served as Chairman of Nektar Therapeutics (formerly, Aerogen Inc.) from 1998 to June 30, 2005 and its Director from 1998 to June 2005. She has been a Director of Intel Corp. since 1993. She has been a Director of McKesson Corp., healthcare supply management company, since 1992. Dr. Shaw served as a Director of OfficeMax Inc. (formerly, Boise Cascade Corp.) from 1994 to April 20, 2006. Dr. Shaw received a BSc and PhD in Physiology from Birmingham University in England.
Jim Woody M.D, PhD
Dr. Woody is a partner at Latterrell Venture Partners and a veteran of the industry with more than 25 years of biomedical research and management experience. Jim was formerly President of Roche Bioscience in Palo Alto, CA. where he had responsibility for all bioscience research and development. Previously, Jim served as Chief Scientific Officer and Senior Vice President of R & D for Centocor, where he was responsible for the discovery and early clinical development of antibody and peptide-based therapeutic products. While at Centocor, Jim developed Remicade, the first of the TNF inhibitor biologics, as well as ReoPro, a novel platelet-blocking drug used in conjunction with angioplasty.
Prior to Centocor, Jim served as Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. In that role, he was responsible for a wide range of medical research and development activities ranging from transplantation research to infectious diseases. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War, and was awarded the US Navy Legion of Merit for his service.
Jim holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. Jim has authored or co-authored over 140 publications.
Phillip Young
Mr. Young is a partner at USVP. With a long tenure in venture capital, Phil has had the pleasure of working with many entrepreneurs. In fact, he's recruited a number of USVP's partners from the ranks of entrepreneurs over the years, most recently Casey Tansey. Whether it's helping a serial entrepreneur scout out his next company, or helping portfolio companies recruit the best possible management team, Phil enjoys the role of coach and mentor.
"Ultimately companies are run by the CEO and management team. Good board members know that the CEO, and only the CEO, makes both the final decisions and manages the execution. But good CEOs will solicit substantive input from their board, and benefit from the dialectic resulting from the meaningful debate of issues at the board level. I really enjoy the process when it's useful."
Phil has finely honed his sense for effective contribution to the companies he advises:
"Sometimes it's best to run alongside the CEO, other times it's best to coach from the sidelines."
Execution is management's responsibility, but board members can be useful sounding boards. "Increasingly, business models are less straightforward. It's helpful to draw out the board's expertise and experience from seeing recurring patterns across industries and over time."
Prior to joining USVP in 1990, Phil spent four years with Concord Partners, Dillon Read's venture capital operation in Palo Alto. With a specialty in the medical device industry, Phil has watched the evolution of new methodologies, such as the emergence of minimally-invasive treatments, into increasingly diverse and pervasive applications.
"In this industry, you need to look at the clinician's perspectives on the market opportunity as well as the investment and technology sides," notes Phil. "Minimally-invasive procedures are still in their infancy."
Phil's investment interests aren't confined to medical devices and biotechnology, however. Recently he's been active in online advertising, a more than $10 billion industry growing at nearly 30 percent a year.
"A critical need in online advertising is helping companies find scalable business models that work," notes Phil.
Like other USVP partners, Phil arrived with extensive operating experience. He was President and CEO of Oximetrix, a manufacturer of critical care instruments and disposables, where he spent eight years growing the privately held venture-backed company from $1 million in revenues to nearly $50 million. Prior to Oximetrix, Phil spent six years at New Court Securities in venture capital and corporate finance, two years as a management consultant with McKinsey & Co., and six years on Admiral Rickover's project management staff at the Atomic Energy Commission.
He has represented USVP on the boards of Aerogen, CardioThoracic Systems, CardioVascular Imaging Systems, CoCensys, Compugen, FemRx, Penederm, 3Dfx Interactive, Vical and Xoma—all of which became public companies, and on the boards of RelayHealth and St. Francis Medical Technologies which were acquired. Currently he sits on the boards of Zoran, a public company, and privately held Aptus Endosystems, Bayhill Therapeutics, Claria, Dotomi, Synarc, Talima Therapeutics, and Timi3 Systems. He also serves on the Board of Trustees of Cornell University and as Chairman of the Board of eCornell, the university's online distance learning subsidiary.
Phil earned a B.M.E. from Cornell University with High Distinction, an M.S. in Engineering Physics from George Washington University, and an M.B.A. with High Distinction from Harvard, where he was a Baker Scholar.
Phil enjoys photography, cooking and spending time with his wife in the South of France. He has two daughters and three grandchildren.